Jun 14, 2024, 16:10
Ghassan Abou-Alfa on a paper by Arndt Vogel et al.
Ghassan Abou-Alfa, a Medical Oncologist at Memorial Sloan Kettering Cancer Center, shared a post on X:
“Final firm proof of pemigatinib open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 at ESMO Open.
Great international and successfully led teamwork of Memorial Sloan Kettering Cancer.”
Read further
Source: Ghassan Abou-Alfa/X